In Brief
Heisler et al. demonstrate that prion protein intracellular transport is important for the progression of prion disease. They identify a regulatory mechanism of bidirectional prion protein vesicle trafficking and propose a novel transport pathway that connects intracellular lysosomal degradation with extracellular exosome trafficking under neurodegenerative conditions. ) modulates cell adhesion and signaling in the brain. Conversion to its infectious isoform causes neurodegeneration, including Creutzfeldt-Jakob disease in humans. PrP C undergoes rapid plasma membrane turnover and extracellular release via exosomes. However, the intracellular transport of PrP C and its potential impact on prion disease progression is barely understood. Here we identify critical components of PrP C trafficking that also link intracellular and extracellular PrP C turnover. PrP C associates with muskelin, dynein, and KIF5C at transport vesicles. Notably, muskelin coordinates bidirectional PrP C transport and facilitates lysosomal degradation over exosomal PrP C release. Muskelin gene knockout consequently causes PrP C accumulation at the neuronal surface and on secreted exosomes. Moreover, prion disease onset is accelerated following injection of pathogenic prions into muskelin knockout mice. Our data identify an essential checkpoint in PrP C turnover. They propose a novel connection between neuronal intracellular lysosome targeting and extracellular exosome trafficking, relevant to the pathogenesis of neurodegenerative conditions.
INTRODUCTION
Prion diseases, also known as transmissible spongiform encephalopathies, are infectious neurodegenerative disorders leading to synaptic impairment, neuronal loss, brain spongiform vacuolation, and death. Among others, they include scrapie in sheep, bovine spongiform encephalopathy in cattle, and Creutzfeldt-Jakob disease (CJD) in humans (Ciechanover and Kwon, 2015; Collinge, 2001) . The cellular prion protein (PrP C ) is a cell surface glycosylphosphatidylinositol (GPI)-anchored protein expressed in neurons and various tissues. Misfolding of PrP C into its abnormal isoform (PrP Sc ) through template-assisted selfreplication is pathogenic, and PrP Sc is the key component of the proteinaceous infectious particle termed ''prion'' (Colby and Prusiner, 2011) . Although prion structure, replication, and the mechanisms of pathogenesis have been extensively analyzed (Aguzzi and Lakkaraju, 2016; Biasini et al., 2012; Mays and Soto, 2016) , PrP C vesicle trafficking and the regulation of PrP C turnover are barely understood.
PrP C follows the secretory pathway toward the plasma membrane. Cell surface PrP C functions through interactions with cell adhesion and signaling proteins (Aguzzi and Lakkaraju, 2016; Biasini et al., 2012; K€ uffer et al., 2016) and can be subject to proteolytic cleavage . Upon internalization at the plasma membrane, it passes endosomes and multivesicular bodies (MVBs) and has a relatively short half-life, mainly because of its degradation in lysosomes (Borchelt et al., 1990; Campana et al., 2005; Mays and Soto, 2016) . Alternatively, parts of the PrP C pool are either recycled back to the cell surface (Sunyach et al., 2003) or undergo exosome secretion into the extracellular lumen following fusion of MVBs with the plasma membrane (Coleman et al., 2012; Fevrier et al., 2004) . Exosomes are considered to contribute to the intercellular communication in the brain and to spread toxic amyloid proteins, including pathogenic prions, during disease (Fevrier et al., 2004; Saá et al., 2014) . Whether and how intracellular vesicle transport regulates prion protein membrane levels and/or exosome trafficking and, thus, might change the progression of prion disease remains to be shown. Motor proteins power ATP-dependent cytoskeleton-based transport of various cargoes between subcellular compartments and organelles (Hirokawa et al., 2010; Kneussel and Wagner, 2013) . Microtubule (MT)-based transport is mediated by kinesin family proteins (KIFs) and cytoplasmic dyneins, many of which exist as multimeric assemblies of heavy chains, light chains, and/or accessory factors that mediate the specificity of cargo assembly and their transport direction (Guzik and Goldstein, 2004; Kneussel et al., 2014; Maeder et al., 2014) . Bidirectional vesicular transport of PrP C in axons depends on kinesin-1 and cytoplasmic dynein (Encalada et al., 2011) . In a ''coordination model,'' PrP C -containing vesicles simultaneously associate with these opposite-directed motor proteins, whereas only a subset of them is active at a given time (Encalada et al., 2011) . This suggests that transport regulation requires additional accessory factors and regulatory mechanisms to determine the transport direction and subcellular targeting of vesicular PrP C cargo.
Muskelin was originally identified as a mediator of cell adhesive responses and intracellular signaling (Adams et al., 1998; Valiyaveettil et al., 2008) . With respect to the endocytosis of gamma aminobutyric acid type A (GABA A ) receptors in neurons, muskelin has been shown to play critical regulatory and cargo adaptor functions at specific motor-cargo complexes (Heisler et al., 2011) . Muskelin acts as a regulatory component in the inward-directed transport of GABA A receptors (GABA A Rs) through myosin VI motors and, furthermore, connects GABA A Rs directly to the dynein motor complex. Its ability to associate with actinand microtubule-based motor protein complexes is unique (Heisler et al., 2011) . With respect to GABAergic synaptic transmission, muskelin has been suggested to balance hippocampal network oscillations (Heisler et al., 2011) and has recently been identified as a potential risk factor for early-onset bipolar disorders (Nassan et al., 2017) . At the molecular level, distinct patterns of oligomerization regulate the differential subcellular localization of muskelin between the cytosol and the nucleus (Delto et al., 2015) .
In this study, we identify muskelin as a critical coordinator of bidirectional PrP C vesicle trafficking. Neurons derived from muskelin knockout mice reveal impairments in inward PrP C transport and subsequent changes in lysosomal PrP C degradation. This is accompanied by an increase in PrP C cell surface levels and a release of exosomes with higher PrP C content, providing the first molecular connection between intracellular and extracellular prion protein trafficking. Consistent with this view, muskelin deficiency in vivo leads to significantly accelerated disease progression upon injection of infectious prions in mice. Our data identify a novel cellular pathway that contributes to the pathophysiology of prion disease. Controlling muskelindependent vesicle trafficking may become relevant for the development of neuroprotective treatment strategies.
RESULTS

PrP
C Associates with Muskelin at Dynein-Driven Vesicles To identify neuronal cargoes associated with the transport regulator muskelin, we immunopurified intact vesicles (in the absence of detergent) derived from neuroblastoma (N2a) cells expressing myc-tagged muskelin. A prominent factor detected was the cellular prion protein (PrP C ), which displayed robust enrichment at myc-muskelin-positive vesicles ( Figure 1A ). Amyloid precursor protein (APP), previously shown to associate with PrP C (Kaiser et al., 2012) , and the unrelated synaptic vesicle protein synaptophysin served as specificity controls. Electron microscopy analysis upon immunogold double labeling confirmed the coexistence of PrP C and myc-muskelin at a subset of intracellular N2a cell vesicles ( Figures 1B, 1C , and S1K). Also, immunostaining for endogenous PrP C and muskelin revealed frequent punctate colocalization in dendrites of cultured hippocampal neurons ( Figures 1D-1F ). Following sucrose gradient centrifugation of vesicle-enriched brain fractions, we observed PrP C and muskelin cofractionation both in the absence and presence of detergent ( Figures 1G and 1H ). Both proteins, therefore, associate at a subset of intracellular vesicles, possibly within one protein complex. PrP C intracellular trafficking involves active motor proteindependent transport (Encalada et al., 2011) . However, little is known about the factors that regulate the targeting and rearrangement of PrP C between intracellular compartments. We therefore addressed whether PrP C might be associated with a previously described muskelin-dynein transport complex (Heisler et al., 2011) . In this context, muskelin directly binds to dynein intermediate chain (DIC), acting as a cargo adaptor for inward GABA receptor transport. In co-immunoprecipitation (coIP) experiments, endogenous muskelin and DIC coprecipitated with PrP C from vesicle-enriched N2a cell fractions in the presence of Triton X-100 ( Figure 1I ), indicating their triple association. Consistently, precipitation of either muskelin, DIC, or PrP C led to coprecipitation of the other two binding partners ( Figures  S1A-S1C ). The kinesin-1 family member KIF5C was also detected within this complex (Figures S1A-S1C), with dynein and KIF5C known to simultaneously associate with transport vesicles (Encalada et al., 2011; Fu and Holzbaur, 2014) . We further performed coIP of endogenous proteins using vesicle-enriched fractions from mouse brain. Again, DIC-specific antibodies coprecipitated muskelin and PrP C in a neuronal context (Figure 1J) , whereas muskelin-specific antibodies coprecipitated PrP C and DIC ( Figure 1K ). However, muskelin's interaction partner GABA A R was not found to share PrP C -containing vesicles (Figures S1D and S1E), whereas the PrP C -associated transmembrane protein LRP1, but not LRP/LR, was detected in muskelinPrP C -positive vesicular precipitates (Figures S1F-S1H). Furthermore, lipid microdomains likely stabilize the association between PrP C and muskelin (Figures S1I and S1J). Together, we conclude that PrP C is part of a larger protein complex at intracellular transport vesicles, comprising the regulatory transport factor muskelin in association with the plus and minus end-directed motors KIF5C and dynein.
Muskelin Undergoes Cotransport with PrP C and
Regulates PrP C Vesicle Dynamics
To investigate whether muskelin undergoes cotransport with PrP C over time, we analyzed the mobility of monomeric red fluorescent protein (mRFP)-muskelin and yellow fluorescent protein (YFP)-PrP C fluorescent particles in live hippocampal neurons. Similar as reported for axonal compartments (Encalada et al., 2011) , time-lapse video microscopy revealed highly mobile YFP-PrP C -containing vesicles within dendrites of wild-type neurons ( Figure 2A ; Video S1). About 50% of YFP-PrP C vesicles were mobile, with roughly equal amounts moving either toward the tips of dendrites (outward) or toward the soma (inward) (Figure 2B) . Consistent with our binding studies (Figure 1 ), individual particles underwent bidirectional cotransport with mRFP-muskelin over distances of several micrometers ( Figure 2C , diagonal lines). Notably, by analyzing YFP-PrP C vesicle mobility in agematched neurons obtained from muskelin knockout (KO) mice, we found YFP-PrP C transport to be strongly decreased (Figure 2D, straight vertical lines; Video S2) . In fact, the number of mobile YFP-PrP C vesicles was decreased by about half, accompanied by an increase in the percentage of stationary vesicles ( Figure 2E ). A reduction of PrP C vesicle motility was also observed for axonal compartments ( Figure S2J ). In contrast, Texas red-labeled transferrin conjugates (control) revealed unaltered transferrin turnover in muskelin knockout neurons ( Figures  S2A-S2C ). The observed changes in YFP-PrP C transport upon muskelin depletion were mainly due to a pronounced reduction in inward-directed YFP-PrP C vesicle numbers but also due to reduced outward PrP C trafficking in axons and dendrites (Figures 2E, S2K, and S2L) . Moreover, within the population of remaining dendritic mobile vesicles, single-particle analysis detected significant reductions in average YFP-PrP C run lengths, velocities ( Figures S2D-S2I ), and net displacements (Figures 2F and 2G, insets) for both directions in the absence of muskelin. Because distributions of net displacements provide a measure of activity or number of opposite polarity motors (Encalada et al., 2011) , we performed a cluster mode analysis by fitting population distributions observed in wild-type (WT) and muskelin knockout neurons with predicted Gaussian modes. Matching previous observations (Encalada et al., 2011) , the sum of two Gaussians fitted best for outward-and inward-directed YFP- (J and K) CoIPs from vesicle-enriched brain fractions using DIC-specific (J) and muskelin-specific (K) antibodies in the presence of Triton X-100 (n = 3 exp.). Data represent mean ± SEM. Statistical analysis: paired Student's t test (**p < 0.01). See also Figure S1 .
PrP C distributions in wild-type neurons (Figures 2F and 2G, blue arrows) . Notably, muskelin deficiency not only triggered outward and inward shifts from higher to lower displacement modes but also caused a decrease in the number of Gaussian amplitudes, indicating motor number or activity changes in the absence of muskelin ( Figures 2F and 2G , red arrows). Altogether, a higher change in net displacements was observed for inwarddirected YFP-PrP C vesicles in muskelin knockout neurons (Figure 2H) . Our data therefore suggest that muskelin, besides its involvement in motor-cargo association, functionally coordinates the directionality of PrP C vesicle transport. (Campana et al., 2005; Veith et al., 2009) , followed by either lysosomal PrP C degradation (Luhr et al., 2004) or the release of PrP C -containing exosomes (Campana et al., 2005; Fevrier et al., 2004) . Analysis of total PrP C protein content in muskelin knockout brain lysates was comparable with wild-type controls ( Figures 3A and 3B ), indicating that muskelin depletion does not alter overall PrP C levels.
To examine whether the observed impairment of PrP C vesicle transport in knockout neurons (Figure 2 ) affects its subcellular distribution, we analyzed PrP C at the plasma membrane. Cell surface biotinylation experiments using live hippocampal muskelin knockout neurons revealed significantly increased PrP C levels at the cell surface ( Figures 3C and 3D ). This finding was confirmed by live immunostaining, which detected elevated PrP C plasma membrane intensities with larger areas covered ( Figures 3E-3G ), whereas the signaling receptor TrkB (control) did not show increased plasma membrane levels upon muskelin depletion ( Figures S3A-S3E ). To explore PrP C surface enrichment further, we next performed a single-cluster analysis. In line with PrP C localization to lipid rafts (Biasini et al., 2012; Campana et al., 2005; Puig et al., 2014; Zurzolo and Simons, 2016) , PrP C average cluster size and its cumulative distribution were shifted to higher values in muskelin knockout neurons ( Figures  3H and 3J ), whereas cluster numbers per dendrite segment remained equal ( Figures 3H and 3I ). Although we did not observe a role for the minus end-directed actin-based motor myosin VI in PrP C cell surface turnover ( Figures S3F-S3I ), overexpression of myc-muskelin per se lowered PrP C surface levels in an N2a cell biotinylation approach ( Figures 3K and 3L ), underlining muskelin's impact on PrP C plasma membrane localization. We therefore asked whether muskelin deficiency functionally acts on the generation of shed-PrP, a prion protein fragment released from the plasma membrane through metalloprotease ADAM10-mediated cleavage (Endres et al., 2009) . Notably, an antibody specific to this PrP fragment ( Figure S3J ) revealed significantly increased levels of shed-PrP in muskelin knockout brain lysates ( Figures 3M and 3N ), confirming elevated cell surface PrP C in muskelin KOs. Given that total PrP C brain levels remained equal across genotypes ( Figure 3A ), these observations point to a subcellular redistribution of PrP C in the absence of muskelin.
We next addressed whether interference with bidirectional cytoskeletal transport in general could explain the increased cell surface PrP C upon muskelin deficiency. Cell surface biotinylation experiments in hippocampal cultures following application of the dynein ATPase-specific inhibitor ciliobrevin revealed net PrP C plasma membrane accumulations upon chronic ciliobrevin treatment over time (Figures 4A and 4B) . Overexpression of the functional dynein inhibitor GFP-dynamitin, known to also affect kinesin-mediated transport, caused a similar increase in PrP C levels at the plasma membrane ( Figures 4C and 4D ).
Interestingly, competitive overexpression of muskelin's isolated LisH and C-terminal to LisH (CTLH) motif fused to GFP (GFPLisH MK ), a peptide harboring the muskelin-dynein direct binding site (Heisler et al., 2011) , further mimicked this effect (Figures 4C and 4D) , indicating that bidirectional PrP C vesicle trafficking requires the muskelin-dynein interface but may also affect kinesin-mediated transport. Although muskelin likely acts on the level of activity regulation of opposing polarity motors in this context (compare with Figures 2D-2H ), we also observed increased binding of DIC to PrP C in coIPs from vesicle-enriched N2a cell fractions following overexpression of myc-muskelin (Figures 4E and 4F) . Notably, the same experiment revealed reduced KIF5C binding to PrP C in a muskelin-enriched environment, indicating that muskelin also modifies the physical association of opposing polarity motors at PrP C vesicles. This prompted us to test competitive overexpression of the muskelin LisH and CTLH motif to directly analyze muskelin-dependent PrP C transport in neurons. Consistent with our previous analysis in muskelin knockout neurons ( Figures 2D-2H ), the competitive interference with muskelin/dynein interactions in wild-type cells also led to significant reductions in the percentage of mobile YFP-PrP C vesicles upon single-particle tracking in dendrites (Figures 4G and 4H) and axons (Figures 4J and 4K) . These results were mainly due to reduced inward-directed PrP C mobility because outward-directed mobility was less affected (Figures 4I and 4L) . Under conditions of inward-directed transport inhibition in muskelin-depleted neurons, a net outward-directed flux may therefore be causal in re-routing PrP C to the cell surface membrane ( Figures 3C-3N ). In general, we observed PrP C distribution across secretory, recycling, and endocytic compartments, with recycling endosomes displaying a substantial fraction of PrP C turnover ( Figures S4A and S4B ), whereas muskelin knockout neurons did not show obvious defects in intracellular vesicle biogenesis ( Figures S4C-S4E ). Accordingly, of the two major recycling routes in neurons, the Rab5-Rab4 pathway showed significantly increased PrP C content, whereas PrP C remained equally localized to Rab11 compartments in the absence of muskelin ( Figures 4M and 4N ). Taken together, plasma membrane turnover of PrP C critically depends on bidirectional vesicle transport regulated through muskelin. We therefore asked whether muskelin controls prion protein trafficking at the late endosome-lysosome pathway, regulating the removal and degradation of plasma membrane proteins.
Muskelin Regulates PrP C Lysosomal Targeting versus
Exosomal Release Besides its role in endocytic vesicle trafficking, muskelin is present at MVBs and regulates lysosomal degradation of neurotransmitter receptors (Heisler et al., 2011 (Borchelt et al., 1990) , endogenous PrP C displayed frequent colocalization with LAMP-1 in the somata of wild-type neurons, as expected. However, the colocalization rates significantly declined upon muskelin depletion (Figures 5C and 5D), whereas a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor colocalization with LAMP-1-positive organelles (control) remained unaltered (Figures S5A and S5B) . Muskelin may therefore facilitate PrP C vesicle transport toward neuronal somata for lysosomal degradation. Consequently, we monitored the fate of PrP C in live hippocampal neurons using a degradation assay based on cell surface biotinylation over time. In wild-type neurons, endogenous PrP C levels at time point 0 min were reduced by more than 50% after 14 hr (Figures 5E and 5F, gray bars) . This degradation of membrane-associated PrP C was largely prevented in the presence of leupeptin, an inhibitor of several lysosomal cysteine, serine, and threonine proteases but not by MG132 ( Figures S5C and  S5D ), a proteasomal inhibitor known to interfere with the degradation of cytosolic PrP C that escapes vesicular pathways (Yedidia et al., 2001) . Notably, in muskelin-deficient neurons, the decline of PrP C was markedly reduced (Figures 5E-5G, black bars), indicating a critical role of muskelin in PrP C lysosomal targeting. Also, the addition of leupeptin had no further effect on the amount of PrP C (Figures 5E and 5F, black bars), suggesting that muskelin depletion is sufficient to interfere with PrP C degradation. We next asked whether reduced lysosomal PrP C degradation could be due to the observed inhibition of inward PrP following myc-muskelin overexpression ( Figures 5M and 5N ).
In conclusion, these data suggest a differential regulation of PrP C lysosomal targeting and degradation via muskelin.
Interestingly, with regard to a potential inhibition of PrP C lysosomal targeting, we found the amount of PrP C to be significantly altered at secreted exosomes. By analyzing exosomes purified from muskelin knockout neuronal culture medium, a 55% increase in exosomal PrP C content was observed compared with wild-type controls ( Figures 6A and 6B) . However, the number of exosomes secreted as well as their average diameter remained equal across genotypes ( Figures 6C and 6D and exosome release are functionally connected through muskelin-dependent vesicle transport.
Muskelin Critically Determines Prion Disease Progression
Alterations in PrP C levels at the neuronal surface membrane have been shown to affect incubation times in prion diseases (Altmeppen et al., 2015; Resenberger et al., 2011; Sandberg et al., 2011) . Moreover, cells release PrP C and PrP Sc in association with exosomes (Coleman et al., 2012; Fevrier et al., 2004; Saá et al., 2014) , and increased exosome release in vitro has revealed a corresponding increase in intercellular transfer of prion infectivity (Guo et al., 2016) . Because both the PrP C plasma membrane amount and exosomal load were significantly increased in muskelin-deficient neurons, we investigated a potential effect of muskelin on the course of prion disease in an in vivo context. Neuropathological investigation of hippocampi in terminal prion disease also revealed similar pathological changes, including PrP Sc deposition, microgliosis, and astrocytosis, irrespective of genotypes or prion administration routes ( Figure 7C , intraperitoneal infections are shown). Intraperitoneal prion infection (low dose) led to the expected incubation times (Glatzel et al., 2005) until the onset of terminal prion disease in mice, with 235 days on average in wild-type controls ( Figure 7D ). Notably, muskelin knockout mice showed significantly reduced incubation times with a mean of 210 days ( Figure 7D ). Moreover, incubation times until onset of terminal prion disease were also significantly reduced in muskelin knockout mice (142 days versus 158 days in wild-type mice) following intracerebral infection with RML prions (high dose) ( Figure 7E ). In contrast, we did not observe any major deficits in aged uninfected muskelin knockout mice compared with the wild-type controls ( Figure S7 ; Tables S1  and S2 ). Collectively, these findings demonstrate a critical role for muskelin in the onset of terminal prion disease. To examine whether muskelin also affects the progression of prion disease, we analyzed muskelin knockout mice 75 days after intracerebral inoculation with RML prions. Because muskelin depletion impairs both vesicular PrP C inward trafficking and lysosomal PrP C degradation (Figures 2, 4 , and 5), we quantified the distribution of PrP C -Lamp-1 double-labeled structures, which, in neurites, mainly represent late endosomes (CA1 molecular layer ML]) that undergo transport toward the soma and maturate into lysosomes (CA1 pyramidal cell layer [PCL]) ( Figures  8A-8D ; Cheng et al., 2018) . Previous studies reported impairments of the endo-lysosomal system with characteristic PrP accumulations within neurites during the early stages of prion disease progression (Laszlo et al., 1992; Shearin and Bessen, 2014; Shim et al., 2016) . Accordingly, we observed a similar PrP C -Lamp-1 redistribution 75 days after prion infection in wild-type mice. Notably, muskelin deficiency led to an even higher redistribution of PrP C -Lamp-1 vesicles toward the molecular layer (Figures 8A-8D ) and also increased their cluster size within the neurite segment ( Figure 8E ). These data suggest that impaired inward-directed PrP C transport and degradation in the absence of muskelin promote PrP C neurite accumulation during prion disease progression. In line with this view, we further detected significantly accelerated PrP Sc accumulation in muskelin-deficient brains 75 days after infection with RML prions (Figures 8F and 8G) . In summary, our data identify essential components of bidirectional PrP C vesicle transport ( Figures 8H-8K ). They propose a novel connection between intracellular lysosomal targeting and extracellular trafficking and highlight its contribution to the pathology of prion disease.
DISCUSSION
In this study, we identify the transport factor muskelin as a core component in regulating subcellular trafficking of PrP C . Muskelin binds to PrP C in association with cytoplasmic dynein and KIF5C (n = 9 wild-type and 8 knockout mice) and intracerebrally (n = 9 wild-type and 9 knockout mice) prion infection. Statistical analysis: log rank test (i.p.: *p = 0.0126, chi-square test = 6.231; intracerebrally: **p = 0.0091, chi-square test = 6.799). See also Figure S7 and Tables S1 and S2. and is essential for efficient PrP C vesicle inward trafficking and degradation. Our findings indicate that, in the absence of muskelin, PrP C is not properly targeted toward the lysosome but, instead, is recycled to the plasma membrane and sorted for extracellular trafficking through exosomal carriers. Consequently, upon challenge with pathogenic prions, muskelin deficiency leads to accelerated prion disease progression. Our data support the study by Encalada et al. (2011) , who reported stable PrP C vesicle association with kinesin and dynein motor proteins in axons, with their activities being tightly regulated. In addition to this study, we also observed high PrP C outward and inward mobility within neuronal dendrites. Neurons deficient for the directly associated dynein adaptor muskelin (Heisler et al., 2011) were affected in both outward and inward PrP C vesicle trafficking, supporting a tight regulation of opposing kinesin and dynein motors. In this context, muskelin may modulate the number or activity of opposing polarity motors, as indicated by coIP and analysis of vesicle dynamics. These data connect to previous findings, where motor protein-associated transport factors were shown to essentially regulate bidirectional vesicle trafficking (Colin et al., 2008; Fu and Holzbaur, 2013; Gunawardena et al., 2013) . Furthermore, impaired bidirectional 
(legend continued on next page)
transport is associated with neurodegenerative disorders such as Huntington's disease (Colin et al., 2008; Fu and Holzbaur, 2014; Kratter et al., 2016; Saudou and Humbert, 2016) or Alzheimer's disease (Fu and Holzbaur, 2013; Gunawardena et al., 2013; Wu et al., 2011) . In this study, muskelin genetic depletion or competitive interference with muskelin-dynein binding mainly impaired inward-directed PrP C transport in dendrites and axons.
Although microtubule polarity is rather mixed in dendrites, mechanisms such as differential association of distinct transport complexes with oppositely oriented microtubules (e.g., through crosstalk with microtubule associated proteins (MAPs) or microtubule posttranslational modifications) might allow for directed net transport of vesicular cargo in dendrites. Therefore, muskelin in complex with dynein, KIF5C, and PrP C , may coordinate inward over outward vesicle transport of prions.
The biosynthesis of PrP C is not distinct from other GPIanchored, plasma membrane-bound, or secreted proteins (Mays and Soto, 2016; Puig et al., 2014; Zurzolo and Simons, 2016) . Plasma membrane PrP C is constitutively internalized and recycles back to the surface (Borchelt et al., 1990; Campana et al., 2005) . When entering the degradation pathway, cells may remove PrP C by lysosomal (Cortes et al., 2013; Marzo et al., 2013; Okemoto-Nakamura et al., 2008) or proteasomal degradation via the endoplasmic reticulum-associated protein degradation (ERAD) pathway (Sassa et al., 2010; Yedidia et al., 2001) , with clearance at lysosomes being prominent over removal at proteasomes (Goold et al., 2015; Marzo et al., 2013) . PrP Sc colocalizes with late endosomes and lysosomes (Sassa et al., 2010) , and inhibition of cathepsin function (Luhr et al., 2004) or the use of anti-prion intrabodies (Vetrugno et al., 2005) interferes with its lysosomal clearance. These findings are consistent with the pronounced degradation of PrP C at lysosomes in this study.
Furthermore, through identification of muskelin as an endogenous factor that associates with PrP C to facilitate its lysosomal targeting and degradation, our data provide novel mechanistic insights into how PrP C trafficking is intrinsically regulated.
It is conceivable that elevated PrP C membrane levels contribute to enhanced susceptibility toward prion disease in muskelin knockout mice. In fact, absence of the PrP C sheddase ADAM10 in neurons also leads to elevated PrP C cell surface levels and, in a prion disease context, to increased PrP Sc formation and decreased incubation times (Altmeppen et al., 2015) . Interestingly, the plasma membrane and MVBs have both been suggested as principal sites of PrP C -to-PrP Sc conversion (Yim et al., 2015) . Diminished degradation and, consequently, PrP accumulation at these compartments in prion-infected muskelin knockout mice may therefore accelerate prion conversion and its release via exosomes (Yim et al., 2015) . In this context, incubation times to prion disease following intraperitoneal administration are thought to predominantly monitor altered intracellular transport and intercellular spread of prions (Brandner et al., 2000) . Our knockout data support and extend this view by showing that both elevated PrP C at the plasma membrane and on exosomes following interference with lysosomal PrP C trafficking requires muskelin and enhances prion susceptibility. Different hypotheses are proposed by which prion infectivity spreads to other cells: direct cell-to-cell contact proteolytic shedding, tunneling nanotubes, and exosomes. Although these mechanisms are not mutually exclusive, exosomal release of prion protein has been reported by several laboratories, and both PrP C and PrP Sc are efficiently sorted into and secreted via exosomes (Coleman et al., 2012; Falker et al., 2016; Fevrier et al., 2004) . In vitro, a recent study confirmed a direct relationship between PrP release via exosomes and intercellular prion dissemination. Although stimulation of exosome release with an ionophore led to a corresponding increase in intercellular transfer of prion infectivity, inhibition of exosome release decreased intercellular prion transmission (Guo et al., 2016) . These findings are consistent with our observations in muskelin knockout mice, characterized by higher exosomal PrP C levels and accelerated PrP Sc accumulation accompanied by decreased incubation times to onset of terminal disease following prion challenge. Muskelin knockout mice may therefore represent the first in vivo model to support a relationship between exosome release and intercellular transfer of prion infectivity.
In general, the field of intercellular exchange via exosomes in the brain is rapidly emerging (Rajendran et al., 2014) . The mechanisms involved in exosome cargo sorting, biogenesis, and secretion are now assembling into a broader picture (Lo Cicero et al., 2015) . Moreover, growing evidence suggests important physiological roles for exosome-mediated communication in processes such as neuronal development, nerve regeneration, synaptic function, and neuron-glia interactions on the neural network level (Rajendran et al., 2014) . In this respect, the muskelin-coordinated transport pathway could not only be involved in disease progression but also regulate PrP C or other exosomal cargoes (e.g., signaling proteins or RNAs) in their physiological context. Regarding neurodegeneration, exosomes also participate in the spreading of b-amyloid (Ab) and tau in Alzheimer's disease, a-synuclein in Parkinson's disease, and mutant SOD1 in amyotrophic lateral sclerosis (Howitt and Hill, 2016; Sanders et al., 2016) . In agreement with muskelin regulating prion protein lysosomal targeting versus exosomal content, inhibition of MVB biogenesis or lysosomal function has been reported to affect the extracellular secretion of Ab (Eitan et al., 2016 ) and a-synuclein (Abeliovich and Gitler, 2016) , respectively. In addition, plasma membrane and exosomal PrP C was identified as a receptor that directly binds Ab with high affinity and modulates the neurotoxic effects of Ab oligomers (Falker et al., 2016; Lauré n et al., 2009) . Muskelin may therefore, in addition, affect other neurodegenerative conditions by promoting lysosomal clearance of PrP C or other disease-associated proteins, limiting their plasma membrane and/or exosomal presentation. In summary, our data identify the first regulatory mechanism in controlling intracellular cytoskeleton-based PrP C vesicle transport. We show that intracellular vesicle trafficking essentially determines PrP C plasma membrane and PrP C exosome content and propose a novel connection between lysosomal and exosomal protein targeting. Finally, the muskelin knockout model unravels a straight relationship between PrP C vesicle transport, PrP C exosome content, and prion pathogenesis in vivo. The muskelin transport pathway may therefore become a novel target in the development of neuroprotective treatment strategies.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mouse Lines and Animal Care
All animal experiments were in strict accordance with the principles of laboratory animal care (NIH publication No. 86-23, revised 1985) and the recommendations in the Guide for the Care and Use of Laboratory Animals of the German Animal Welfare Act on protection of animals. The protocol was approved by the Ethical Committee of the Freie und Hansestadt Hamburg, Amt f€ ur Gesundheit und Verbraucherschutz (Permit number: V 1300/591-00.33). Generation of muskelin knockout mice (Mkln1 À/À ) was previously described (Heisler et al., 2011) . B6;129/SvEv-Mkln1
Gt(OST448976)Lex /J mice were backcrossed to C57BL/6J. Snell's waltzer mice, in which homozygous mutant mice (Myo6 sv/sv ) are functionally null for Myo6, were obtained from The Jackson Laboratory (B6 x STOCK Tyr c-ch Bmp5 se +/+ Myo6 sv /J) and were on a C57BL/6J background. Prion protein knockout mice (Prnp À/À ) (B€ ueler et al., 1992) , mice with a conditional knockout of the metalloprotease ADAM10 in forebrain neurons (Camk2a-Cre:Adam10 À/À ; herein referred to as A10cKO) (Altmeppen et al., 2015; Prox et al., 2013) and transgenic mice overexpressing the prion protein (Tg(Prnp)a20 herein referred to as Tga20) (Fischer et al., 1996) were previously described and on a C57BL/6J background. All mice were maintained in a pathogen-free, temperature-and humidity-controlled vivarium on a 12 h light/dark schedule. Mice had access to standard laboratory chow and water ad libitum. Both male and female mice were included in all of the experiments. The age of mice was chosen in accordance to scientific questions and is specified in the method details section for the different experimental approaches. In general, littermates of the appropriate genotypes were used. For experiments that required higher amounts of mice with the appropriate genotype, animals were collected from sequential littermates (immunoprecipitation on vesicle fraction) or from pure homozygous and wild-type matings (degradation assay or exosome analysis; requiring high amounts of primary hippocampal neurons).
Primary Neuronal Culture
Primary mouse hippocampal neurons were prepared from P0 newborn mice, as previously described (Heisler et al., 2014) , plated at 90,000 to 110.000 cells/well onto poly-L-lysine-(Sigma, Steinheim, Germany) coated 24 well plates (Greiner Bio-One, Kremsm€ unster, Austria) or onto 6 well plates at 600,000 cells/well. Cells were cultured in PNGM Primary Neuron Basal Medium supplemented with PNGM-A Single Quots (PA, OA, NSF-1, L-Glutamine) (all Lonza Group Ltd., Basel, Switzerland) and 100U/mL penicillin and 100mg/mL streptomycin (all Invitrogen, Carlsbad, CA) at 37 C in a humidified incubator with 5% CO 2 . Cells cultured between 11 and 12 days in vitro (DIV9-12) were used for transfection with a calcium phosphate coprecipitation method (Heisler et al., 2014) or with Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
Cell Culture and Transfection HEK293 (#CCL-1573) and N2a (#CCL-131) cells were purchased from American Type Culture Collection (ATCC, Manasas, VA). HEK293 and N2a cells were maintained in DMEM-Glutamax medium supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin and 100mg/mL streptomycin (all Invitrogen, Carlsbad, CA) at 37 C in a humidified incubator with 5% CO 2 . For experiments involving exosome analysis 10% exosome-depleted FBS was used (Thermo Scientific, Waltham, MA). HEK293 cells were grown to 60% confluency before transfection using the calcium phosphate coprecipitation protocol. N2A cells were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) or with ScreenFectÒ A-Plus reagent (InCella GmbH, Eggenstein-Leopoldshafen, Germany) following the manufacturer's protocol.
General Note
Brain tissue and primary cultured hippocampal neurons were used for most experiments where possible. Some of the experiments were carried out in N2a cells or HEK293 cells. This was mainly due to technical reasons, e.g., for assays including overexpression of muskelin or competitive peptides it was not possible to obtain sufficient transfection rates of neurons in order to biochemically study PrP C surface levels, degradation, and exosome content by western blot. Moreover, N2a cells also displayed a suitable experimental model with respect to the reported high PrP C intracellular turnover and release of exosomal PrP C into culture media. Another reason for additional cell line usage was the confirmation of results obtained from brain or neurons through an additional, independent experimental model system (e.g., coIPs based binding studies with antibodies specific for either endogenous muskelin or heterogeneously expressed myc-muskelin).
METHOD DETAILS Molecular Biology
Dynamitin-EGFP was previously described (Palazzo et al., 2001 ). Myc-muskelin in pcDNA3 and mRFP-Muskelin were previously described (Heisler et al., 2011) . To generate GFP-LisH MK the sequences coding for aa172-258 of muskelin (muskelin LisH and CTLH domain) were amplified and cloned into pEGFP-C (Invitrogen, Carlsbad, CA) as EcoRI-SalI fragment. pFusionRed-C (FRed) was purchased from Evrogen (Moscow, Russia). To generate FRed-LisH MK , the GFP in GFP-LisH MK was exchanged with FRed as NheI-EcoRI fragment amplified from pFusionRed-C. The PrP C construct fused to GFP (PrP C -EGFP) was cloned from pDrivemPrP C -EGFP-C1 into pIRES (MCS B) as Sal1-XbaI fragment. The PrP C construct fused to YFP (YFP-PrP C ) was a kind gift from Dr. Sandra E. Encalada (Scripps Research Institute, La Jolla, CA) and Dr. Larry S. Goldstein (UCSD School of Medicine, La Jolla, CA). mRFP-Rab5 (Addgene plasmid #14437) and mRFP-Rab7 (Addgene plasmid #14436) were kind gifts from Dr. A. Helenius (ETH Z€ urich, Switzerland). GFP-Rab6 (Addgene plasmid #31734), GFP-Rab8 (Addgene plasmid #31735) were gifts from Ron Vale (Howard Hughes Medical Institute, San Francisco CA). GFP-rab11 wild-type was a gift from Richard Pagano (Addgene plasmid #12674). We replaced the GFP-fragment by the mCherry-fragment from pmCherry-C vectors (Takara Bio Europe, SAS, St-Germain-en-Laye, France) using EcoRI-BamHI, SacII-BamHI and BglII-SalI restriction sites, respectively. pTomato-Rab4 was previously described (Gromova et al., 2018) . All constructs were verified by dideoxy sequencing.
Antibodies Application Details
The following antibodies were used for immunoprecipitation (IP) and western blotting (WB): mouse anti-Dynein Intermediate Chain (2-4 mg (IP) and 1:3,000 (WB), Chemicon, Hofheim, Germany); rabbit anti-myc (2-4 mg (IP) and 1:3,000 (WB), Sigma, Steinheim, Germany); mouse anti-myc (1:4,000 (WB), Sigma, Steinheim, Germany); mouse anti-PrP (1:1,000 (WB), POM2, A. Aguzzi, Z€ urich, Switzerland; Polymenidou et al., 2008) ; mouse anti-PrP (1:1,000 (WB), POM1, A. Aguzzi, Z€ urich, Switzerland; Polymenidou et al., 2008) ; rabbit polyclonal directed against shed PrP (1:1,000 (WB), detailed information to be found in Figure S3 ); rabbit anti-PrP (4mg (IP) and 1:1000 (WB), ProteinTech Group, Chicago, IL); mouse anti-amyloid precursor protein A4 (1:500 (WB), Chemicon, Hofheim, Germany); mouse anti-Muskelin (4mg (IP) and 1:1000 (WB), Santa Cruz Biotechnology, Heidelberg, Germany); rabbit anti-Muskelin (4 mg (IP) and 1:2000 (WB), Abcam, Cambridge, UK); rabbit anti-Muskelin (4 mg (IP) and 1:500 (WB), ProteinTech Group, Chicago, IL); guinea pig anti-Muskelin (1:500; Heisler et al., 2011; Tagnaouti et al., 2007) ; rabbit anti-GFP (2-4 mg (IP) and 1:4,000 (WB), Sigma, Steinheim, Germany); mouse anti-TRPC1 (1:1,000 (WB), Santa Cruz Biotechnology, Heidelberg, Germany); rabbit antiactin (1:2,000 (WB), Sigma, Steinheim, Germany); mouse anti-g-Adaptin (1:2000 (WB), BD Biosciences, Heidelberg, Germany); rabbit anti-Myosin VI (1:500 (WB), Santa Cruz Biotechnology, Heidelberg, Germany); rabbit anti-NMDAR2B (1:1000 (WB), Abcam, Cambridge, UK); anti-Tsg101 (1:1,000 (WB) BD Biosciences, Heidelberg, Germany); anti-TrkB (1:500 (WB) Cohesion Biosciences, London, UK); rabbit anti-LRP1 (1:10000 (WB), Abcam, Cambridge, UK); rabbit anti-Rpsa (1:1000 (WB), GeneTex, Irvine, CA); mouse anti-TSG101 (1:1,000 (WB), GeneTex, Irvine, CA); mouse unspecific IgG and rabbit unspecific IgG (both 4 mg (IP), Sigma, Steinheim, Germany); peroxidase-conjugated donkey anti-mouse, donkey anti-rabbit and donkey anti-guinea pig (1:15,000 for mouse and 1:20,000 for rabbit (WB), Dianova, Hamburg, Germany); peroxidase-conjugated light chain-specific goat anti-mouse (1:15,000 (WB), Dianova, Hamburg, Germany. The following antibodies were used for immunofluorescence and/or immunohistochemistry: mouse anti-PrP (1:100, POM2, A. Aguzzi, Z€ urich, Switzerland); anti-PrP (Saf 84) (Cayman Chemical, Ann Arbor, USA); mouse antiGluA2 (Chemicon, Hofheim, Germany); guinea pig anti-Muskelin (1:25; Heisler et al., 2011; Tagnaouti et al., 2007) ; rabbit anti-Muskelin (1:50, ProteinTech Group, Chicago, IL); rabbit anti-beta-Tubulin III (1:2,000, Sigma, Steinheim, Germany); guinea pig anti-Map2 (1:1,000, Synaptic Systems, Goettingen, Germany); rabbit anti-Rab4 (1:1,000, GeneTex, Irvine, CA); rabbit anti-Rab5 (1:100, Sigma, Steinheim, Germany); rabbit anti-Rab7 (1:100, Sigma, Steinheim, Germany); rabbit anti-Rab11 (1:100, Cell Signaling Technology, Danvers, MA); rat anti-LAMP1 (1:100, BD Biosciences, Heidelberg, Germany), rabbit anti-KIF5C (1:500, Thermo Scientific, Waltham, MA); rabbit anti-TrkB (1:100 (ICC) Cohesion Biosciences Ltd. London, UK); ionized calcium binding adaptor molecule 1 (Iba1) (Wako Chemicals, Neuss, Germany); GFAP (clone 6F2) (Dako, Glostrup, Denmark) ; Alexa Fluor 488 conjugated donkey anti-rabbit and donkey anti-guinea pig (both 40mg/ml, Invitrogen, Carlsbad, CA); CY3-or CY5-conjugated donkey anti-mouse, donkey anti-rat or donkey anti-rabbit (1:1,000, Dianova, Hamburg, Germany).
Centrifugation and Coimmunoprecipitation
Whole brains of five adult mice were dissected in ice-cold PBS and homogenized in IM-Ac buffer (20 mM HEPES, 100 mM KCl, 5 mM EGTA, and 5 mM MgCl 2 , pH 7.2) with freshly added protease inhibitor cocktail (Roche, Mannheim, Germany), 1 mM PMSF, 5 mM DTT and 2 mM Mg-ATP (all Sigma, Steinheim, Germany). The homogenate was centrifuged at 1,000 x g for 10 min and the resulting postnuclear supernatant further clarified at 10,000 x g for 10 min. The resulting supernatants were processed by another 100,000 x g centrifugation step for 1 h to collect a pellet (P3), typically enriched with intracellular vesicles (Heisler et al., 2014) . 2-4 mg antibodies were coupled to magnetic Dynabeads Protein G or Protein A (Invitrogen, Carlsbad, CA) at 4 C for 4 h with constant rotating. Brain extracts from P3 fractions, N2a cell or HEK293 cell extracts were adjusted to 1% Triton X-100, 1% Octyl-b-D-glucopyranoside or 1% N-Lauroylsarcosine (all Sigma, Steinheim, Germany) prior to incubation with antibody conjugated beads overnight, followed by extensive washing steps with IM-Ac buffer (20 mM HEPES, 100 mM KCl, 5 mM EGTA, and 5 mM MgCl 2 , pH 7.2), IP-buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 5 mM MgCl 2 ) containing 0.5%-1.0% Triton X-100 or with PBS containing 1% Tween-20. Bound proteins were eluted in SDS sample buffer, subjected to SDS-PAGE and analyzed by western blotting.
Sucrose Density Gradient Centrifugation
For sucrose gradient centrifugation, brains of twelve P10 juvenile rats were homogenized in buffered sucrose solution (320 mM sucrose, 2 mM DTT, 1 mM EDTA, 1 mM EGTA, 5 mM MgCl2, 4 mM HEPES, pH 7.4) freshly supplemented with proteinase inhibitor cocktail (Roche, Mannheim, Germany), 1mM PMSF and 2mM ATP. The homogenate was then differentially centrifuged as described above to obtain the intracellular vesicle-enriched pellet (VE). The pellet was resuspended in 1.5 mL of 2 M sucrose solution in absence and/or presence of 1% Triton X-100 and subjected to a linear 0.3-2 M sucrose-density gradient centrifugation. The gradient was centrifuged at 160,000 x g in a SW40Ti rotor (Beckman Coulter, Fullerton, CA) for 12 h at 4 C. Fractions of about 600 mL were collected from the top of the gradient using a defractionator (Labconco, Kansas City, MO). 60 mL of each fraction were used for SDS-PAGE and analyzed by western blotting.
Vesicle Immunoisolation Subcellular fractionation with subsequent immunopurification of vesicles carrying transmembrane proteins was performed as described (Heisler et al., 2014) with slight modifications. In brief, N2a cells were transfected with pcDNA3-myc-Muskelin and homogenized in ice-cold sucrose buffer (320 mM sucrose, 10 mM HEPES, 5 mM EDTA, pH 7.3), freshly supplemented with protease inhibitor cocktail (Roche, Mannheim, Germany) and 1 mM PMSF, 48 h post transfection. Homogenates were centrifuged at 12,500 x g for 8 min and the resulting supernatants were again centrifuged at 40,000 x g for 40 min. Next, supernatants were recovered and centrifuged at 120,000 x g for 1 h. To promote resuspension the resulting pellet (V1 C ) was vigorously stirred for 1 h prior immunopurification. Dynabeads Protein G (Invitrogen, Carlsbad, CA) where washed twice with 0.1% BSA in PBS, incubated with antibodies (5 mg in 0.1% BSA in PBS) for 1 h with constant rotation, washed twice with 0.1% BSA in PBS, once with elution buffer (20 mM Tris; pH 7.4, 0.1% Triton X-100) and 4 times with IP buffer (PBS, 320 mM sucrose, 5 mM EDTA) supplemented with protease inhibitor cocktail (Roche, Mannheim, Germany) and 1 mM PMSF. V1 C vesicle fractions were incubated with antibody precoated beads for 3 h on a rotation wheel and washed 8-12 times with IP buffer. For western blot analysis without interfering with protein-protein interactions, beads were washed with 20 mM Tris, pH 7.4, solubilized for 30 min in elution buffer and boiled in SDS sample buffer prior to SDS-PAGE and western blotting. incubated in blocking solution (4% horse serum (HS), 0.2% Triton X-100) for 30 min. Primary antibodies (anti-Lamp-1 and anti-PrP C POM2) were applied for 2 h floating in 2% HS and 0.1% Triton X-100. Fluorescently labeled secondary antibody incubation was performed for 1 h in 1.5% HS. For western blot analysis, brain samples were homogenized (FastPrep FP120, Qbiogene, Illkirch, France) at 10% (weight/volume, w/v) in buffer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris-HCl pH 8.0) and selected samples were digested with proteinase K (PK) (20 mg/ml) (Roche, Mannheim, Germany) for 1 h at 37 C. Digestion was stopped by addition of 10x sample buffer and boiling for 10 min. Samples were analyzed by SDS-page (AnykD, Biorad, Hercules, USA), transferred to PVDF membranes (BioRad) at 400 mA for 1 hr, blocked for 1 h at room temperature in 5% milk/TBST and incubated overnight at 4 C with anti-PrP antibody POM1 (1:1000; Polymenidou et al., 2008) in blocking buffer or b-actin (1:5,000; Sigma). After incubation for 1 h at room temperature with an HRP-conjugated secondary antibody (1:5000 in blocking buffer), signal was detected with ECL femto reagent (Thermo Scientific) and visualized and quantified with a BioRad ChemiDoc imaging station and Biorad VersaDoc.
Cryo EM Immunodouble Labeling N2a cells were fixed with 4% PFA and 0.1% Glutaraldehyde in Phosphate Buffer pH 7.2 for 1 hr. Thereafter cells were rinsed three times in PBS, collected carefully and transferred to an Eppendorf tube. Cells were spun down and the pellet was suspended in 12% (w/v) gelatin in PBS at 37 C for 5 min. They were again centrifuged and placed on ice for 10-20 min to solidify the gelatin. Cells in the solid gelatin were put into ice-cold buffer and small cubic blocks of 1mm 3 were cut. The blocks were transferred into 2.3 M sucrose in PBS and rotated overnight. Cryoprotected blocks were removed from sucrose and placed on specimen holders and frozen in liquid nitrogen. Ultrathin sections (70nm) were cut and labeled according to a previously described method (Slot and Geuze, 2007) . Briefly, sections were collected on Carbon-Formvar-coated copper grids (Science Services GmbH, Munich, Germany). Antibodies mouse anti-PrP (1:25, POM2, A. Aguzzi, Z€ urich, Switzerland) and rabbit anti-myc (1:50, Sigma, Steinheim, Germany) were recognized with 15 nm and 10 nm large protein A gold secondary antibodies, respectively (purchased from G. Posthuma, University Medical Center Utrecht). This combination was changed against each other in an independent experiment leading to similar results. Ultrathin sections were examined using a Zeiss EM 902.
Surface Biotinylation Assay HEK293 or N2a cells were transfected through a calcium phosphate coprecipitation method or with Lipofectamine 2000, respectively (Heisler et al., 2014) . Primary hippocampal neurons were treated with ciliobrevin either acutely for 60 min at 20 mM final concentration or chronically for 24 h at a 5 mM final concentration. Neurons, HEK293 cells (18 h post transfection), N2a cells (48 h post transfection) or DIV12-14 hippocampal neurons from either wild-type or muskelin knockout mice were then subsequently incubated for 20 min at 4 C with HEPES-buffer containing 1 mM biotinamido-hexanoic acid 3-sulfo-N-hydroxysuccinimid-ester sodium salt (Sigma, Steinheim, Germany). Remaining biotin reagent was quenched by application of 100 mM glycine in HEPES-buffer (twice for 15 min at 4 C). Because low temperature is known to inhibit membrane trafficking and endocytosis, biotinylated cell surface expressed molecules remain at the plasma membrane during these incubations (Heisler et al., 2014) . Cells were then washed with ice-cold PBS and harvested in PBS containing 1% Triton X-100, with freshly added protease inhibitor cocktail (Roche, Mannheim, Germany) and 1 mM PMSF. After 30 min of lysis on ice, followed by a brief centrifugation step at 1,000 x g (5 min, 4 C), 30 ml of the supernatants were loaded on a gel to evaluate the total amounts of PrP C . In case of equal PrP C amounts between sample groups, supernatants were added to 40 ml of equilibrated magnetic streptavidin beads (Dynabeads Myone TM Streptavidin C1, Invitrogen, Carlsbad, CA). Beads were incubated with supernatants for 4 h at 4 C on a rotation wheel, washed 3 times with IP-buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 5 mM MgCl 2 ) containing 1% Triton X-100, collected and boiled in SDS sample buffer prior to SDS-PAGE and western blot analysis.
Degradation Biotinylation Assay
To analyze PrP C degradation, we followed the loss of biotinylated PrP C over a time period of 14 h. To this end surface PrP C on DIV12-14 hippocampal neurons from wild-type or muskelin knockout mice or on N2a cells was biotinylated and washed as described for surface biotinylation assay. Cells (0 min) were then immediately harvested in PBS containing 1% Triton X-100, with freshly added protease inhibitor cocktail (Roche, Mannheim, Germany) and 1mM PMSF, to access the total biotinylated PrP C levels at the cell surface membrane for wild-type and knockout neurons or for N2a cells. In parallel, cells were further incubated at 37 C for 14 h in the preconditioned Primary Neuronal Basal Media (Lonza Group Ltd., Basel, Switzerland) or in N2a cell culture media to let endocytosis and degradation of PrP C occur. During this period cells were either left untreated or treated with 200 mM leupeptin or with 20 mM MG-132 (all Sigma, Taufkirchen, Germany), known to inhibit the proteolytic activity of lysosomes or proteasomes, respectively. Cells were then washed and harvested as described above. After 30 min of lysis on ice, followed by a brief centrifugation-step at 1,000 x g (5 min, 4 C), 30 ml of the supernatants were kept as loading control (Actin detection) and the remaining supernatants added to 40 ml of equilibrated magnetic streptavidin beads (Dynabeads Myone TM Streptavidin C1, Invitrogen, Carlsbad, CA). Beads were incubated with supernatants for 3 h at 4 C on a rotation wheel, washed 3 times with IP buffer (150mM NaCl, 50mM Tris, pH 7.5, 5mM MgCl 2 ) containing 1% Triton X-100, collected and boiled in SDS sample buffer prior to SDS-PAGE and western blot analysis.
Time-Lapse Video Microscopy
Primary hippocampal neurons were prepared as described and cultured on 35 mm glass bottom dishes (Ibidi, Martinsried, Germany). Neurons were transfected at DIV10-11 through a calcium phosphate coprecipitation method as described and used for live cell imaging experiments at DIV12-14. During live imaging hippocampal neurons were kept temperature-(37 C) and CO 2 -(5%) controlled. Images were acquired at an inverted microscope (Nikon Instruments, Amsterdam, the Netherlands) combined with Spinning Disc (Yokogawa, Amersfoort, the Netherlands) Live Cell Confocal (SDC) technology (Visitron Systems Puchheim, Germany). SDC was combined with a charge-coupled device EM-CCD camera (Hamamatsu Photonics, Herrsching am Ammersee, Germany). For single channel live imaging (YFP-PrP C ) a GFP filter was used; images were taken at intervals of every 3 or 5 s for a duration of 5-10 min. For simultaneous double channel recordings (mRFP-Muskelin and YFP-PrP C ) CY3 and GFP filters were used with an optical image splitter or in sequential acquisition mode; images were taken at intervals of every 3 or 5 s for a duration of 5-10 min. For image acquisition a 60x objective (Nikon Instruments, Amsterdam, the Netherlands) was used. Cells at the microscope stage were kept in Primary Neuronal Basal Media (Lonza Group Ltd., Basel, Switzerland) and were temperature (37 C) and CO 2 -controlled (5%) using a live imaging chamber (Visitron Systems Puchheim, Germany). Images at the microscope stage were acquired using the VisiView software (Visitron Systems Puchheim, Germany) and image stacks subsequently loaded into MetaMorph 7.1 (Universal Imaging, Downingtown, PA) for analysis of fluorescent puncta.
QUANTIFICATION AND STATISTICAL ANALYSIS
Live Imaging Data and Particle Tracking Cotransport of mRFP-Muskelin/YFP-PrP C particles was analyzed from image stacks and respective kymographs. Tracking of YFPPrP C particles in wild-type or muskelin knockout neurons was performed by using the MetaMorph 7.1 (Universal Imaging, Downingtown, PA) software. YFP-PrP C trajectories were analyzed only within distal dendrites or within axons and the following definitions were used to calculate transport parameters. Vesicles changing their position less than 2 mm along the x, y coordinates over the entire imaging period were classified as stationary, vesicles changing position by more than 2 mm classified as mobile. Mobile vesicles with overall movement toward distal dendrites were categorized outward and vesicles with overall movement toward the soma were categorized inward. Run length (either outward or inward) was defined as the directed net distance (including directional reversals en route) that particles continuously move until they pause. Pausing was defined as movements of less than 2 mm along the x, y coordinates at a particular position over three image acquisition intervals. Net displacement (either outward or inward) was defined as the directed net distance of particle movement (including directional reversals en route) divided by the total duration of movement until pause. Velocities were defined according to net displacements but particle immobility (< 2 mm) for up to three subsequent acquisition intervals (until as defined pausing) was subtracted from the total duration of movement. For Gaussian fitting and cluster analysis of net displacement distributions data were first explored by using IBM SPSS Statistics 22 (IBM, Armonk, NY) and analyzed by using GraphPad Prism6.07 (GraphPad Software, La Jolla, CA). Wild-type net displacement distributions were non-normal; Muskelin knockout net displacement distributions were normal. Comparisons between wild-type and knockout distributions were performed by using Kolmorogov/Smirnov and Mann-Whitney-U tests. The Omnibus F-test was used to select the optimal fits for each curve and to select the appropriate Gaussian modes.
General Statistical Analysis
The sample size was adjusted according to results of prior pilot datasets or studies that used similar methods or paradigms. Data were analyzed using Microsoft Excel and GraphPad Prism6.07 (GraphPad Software, La Jolla, CA). Prior to analysis, data were explored by using IBM SPSS Statistics 22 (IBM, Armonk, NY), estimated and the variance within the groups was compared. Appropriate statistical tests were then chosen. The statistical tests used are outlined in the corresponding figure legends for each experiment. A two-tailed type I error rate of p < 0.05 was adopted as a yardstick for statistical significance; p = 0.01-0.05 significant (*); p = 0.001-0.01 very significant (**); p < 0.001 highly significant (***). All biological experiments were repeated at least three times using independent cell cultures or individual subjects (biological replications). Quantitative data are reported as mean ± SEM. Error bars represent the SEM.
Western Blot and Confocal Image Data Analysis
For evaluation of relative immunoblot signal intensities, images were acquired using a Chemo-Cam Imager ECL HR 16-3200 (Intas, Gö ttingen, Germany) and signal intensities were analyzed using the ImageJ, version 1.38, software (National Institutes of Health, NIH). Signal intensities were then normalized, as compared to loading control signals for immunoblots. Data were then transformed without changing the ratio between sample groups within one experiment and the mean of control data points was set to 1, in order to provide easier readability. Fluorescence imaging was carried out with an upright Laser-scanning Confocal Microscope Fluoview FV1000 with Olympus Fluoview Software Ver. 2.1.b (Olympus, Hamburg, Germany) or an inverted Leica TCS-SP2 laser scanning confocal microscope (Leica Microsystems, Wetzlar, Germany) using a 63x objective. For simultaneous multiple-channel fluorescence, images were taken in a sequential channel recording mode. Confocal images from multiple individual cells used for statistical analysis were obtained using identical photomultiplier values throughout each experiment. All experiments were at least replicated three times using different culture preparations. Images were saved as overlay TIF-files and further processed offline and analyzed using MetaMorph 7.1 (Universal Imaging, Downingtown, PA). First regions of interests (ROIs) were defined throughout multiple image acquisition frames using the ROI tool. The overlay TIF-files were then separated in green and red channel using the ''color separate'' function and ROI were transferred from the overlay to each channel using the ''transfer region'' function to define identical ROIs. For definition of image thresholds, brightness was adjusted using the ''Inclusive thresholding state'' function. Fluorescence intensity, size, and cluster number measurements were performed using the ''Integrated Morphometry Analysis'' function within MetaMorph to assess the number of objects, the average and total signal intensity, the average and total signal area, the average and single object cluster sizes and the average cluster numbers of identically defined ROIs for each channel. By using the ''colocalization'' tool within Metamorph the area of overlapping signal between channels was analyzed. For either surface labeling analysis or colocalization measurements, one or two dendrites were randomly chosen from the distal parts of a neuron if not stated that neuronal somata were subject to analysis.
